Business
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick
About this update from Vor Biopharma Inc.
[{"type":"image","alt":"Vor Biopharma","displaySize":"","headline":null,"caption":"Vor Biopharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B2LYyFLcnDdgjzJKo4HDhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec","width":300,"height":108}},"lazy":false},{"type":"text","content":"BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois.","length":527,"tagName":"p"},{"type":"text","content":"Late-Breaking Presentation Details","length":34,"tagName":"p"},{"type":"text","content":"Abstract Title: Efficacy and Safety of Telitacicept in Patients with Sjögren's Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study","length":188,"tagName":"p"},{"type":"text","content":"Session: Late-Breaking Posters","length":30,"tagName":"p"},{"type":"text","content":"Date & Time: Tuesday, October 28th, 10:30 AM – 12:30 PM CT","length":62,"tagName":"p"},{"type":"text","content":"In early September, RemeGen announced the acceptance by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China of its Biologics License Application (BLA) for primary Sjögren’s disease, which will become telitacicept’s fourth approved indication in China.","length":300,"tagName":"p"},{"type":"text","content":"About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.","lengt...